CA1300503C - Immunological adjuvant - Google Patents

Immunological adjuvant

Info

Publication number
CA1300503C
CA1300503C CA000534735A CA534735A CA1300503C CA 1300503 C CA1300503 C CA 1300503C CA 000534735 A CA000534735 A CA 000534735A CA 534735 A CA534735 A CA 534735A CA 1300503 C CA1300503 C CA 1300503C
Authority
CA
Canada
Prior art keywords
adjuvant
oil
antigen
saline solution
sterile saline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000534735A
Other languages
English (en)
French (fr)
Inventor
John L. Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Application granted granted Critical
Publication of CA1300503C publication Critical patent/CA1300503C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA000534735A 1986-04-15 1987-04-15 Immunological adjuvant Expired - Lifetime CA1300503C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US852,120 1986-04-15
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant

Publications (1)

Publication Number Publication Date
CA1300503C true CA1300503C (en) 1992-05-12

Family

ID=25312542

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000534735A Expired - Lifetime CA1300503C (en) 1986-04-15 1987-04-15 Immunological adjuvant

Country Status (9)

Country Link
US (1) US4806352A (en:Method)
JP (1) JPS6310736A (en:Method)
AU (1) AU574014B2 (en:Method)
CA (1) CA1300503C (en:Method)
DE (1) DE3712767A1 (en:Method)
ES (1) ES2005166A6 (en:Method)
FR (2) FR2596990B1 (en:Method)
GB (1) GB2189141B (en:Method)
IT (1) IT1205819B (en:Method)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
ES2019728A6 (es) * 1988-09-23 1991-07-01 Univ Southern California Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
FI902821A7 (fi) * 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
CA2106474C (en) 1991-03-19 2004-02-10 R. Martin Emanuele Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
IE921212A1 (en) * 1991-04-19 1992-10-21 Affinity Biotech Inc Convertible microemulsion formulations
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
AU6989094A (en) * 1993-05-27 1994-12-20 Entremed, Inc Compositions and methods for treating cancer and hyperproliferative disorders
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
EP0855906B1 (en) 1995-10-17 2008-02-20 Jagotec AG Insoluble drug delivery
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
IL137734A0 (en) * 1998-02-11 2001-10-31 Res Triangle Pharm Ltd Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2333648C (en) 1998-05-29 2008-10-21 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
BR0009663A (pt) 1999-04-09 2002-04-09 Upjohn Co Composições de vacinas antibacterianas
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
PT1267899E (pt) 2000-03-17 2005-11-30 Pharmacia & Upjohn Co Llc Vacinas de salmonella com ssa inactivados
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
WO2001080828A2 (en) 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
WO2002017883A2 (en) 2000-08-31 2002-03-07 Rtp Pharma Inc. Milled particles
ES2372746T3 (es) * 2000-09-20 2012-01-26 Jagotec Ag Micropartículas de fibrato estabilizadas.
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
DE60127457T2 (de) * 2001-02-22 2007-11-29 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
KR101787309B1 (ko) 2008-12-09 2017-10-18 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
EP2529641B1 (en) 2010-01-29 2015-11-11 Kabushiki Kaisha Mikimoto Clasp for accessory
CN103118701B (zh) 2010-05-14 2017-10-24 百深公司 Ospa嵌合体及其在疫苗中的用途
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
JP2014500267A (ja) 2010-12-08 2014-01-09 ネオヴァクス 強力に不活性化されているがなお高い免疫原性を示すワクチンおよびその製造方法
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
MX348380B (es) 2011-04-07 2017-06-09 Neovacs Pruducto inmunogénico para usarse en vacunas.
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
JP2015524802A (ja) 2012-07-27 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ キメラｏｓｐａ分子を含む組成物およびその使用方法
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN107001449A (zh) 2014-10-15 2017-08-01 芝诺锡拉公司 具有降低的免疫原性的组合物
EP3801628A1 (en) 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Tlr7 peptide conjugates
JP7728560B2 (ja) 2018-07-02 2025-08-25 アユヴィス リサーチ インク． 新規免疫調節小分子
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
US20240424086A1 (en) 2021-09-07 2024-12-26 Universite De Tours Coronavirus fusion protein
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025224251A1 (en) 2024-04-24 2025-10-30 Prokarium Limited Modified microorganisms
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (en:Method) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
FR2596990B1 (fr) 1990-12-07
FR2598622A1 (fr) 1987-11-20
DE3712767A1 (de) 1987-10-22
AU574014B2 (en) 1988-06-23
FR2596990A1 (fr) 1987-10-16
ES2005166A6 (es) 1989-03-01
GB2189141A (en) 1987-10-21
FR2598622B1 (fr) 1990-05-11
AU7156687A (en) 1987-10-22
IT8747855A0 (it) 1987-04-15
IT1205819B (it) 1989-03-31
DE3712767C2 (en:Method) 1991-06-27
GB2189141B (en) 1990-07-25
US4806352A (en) 1989-02-21
JPS6310736A (ja) 1988-01-18
GB8709023D0 (en) 1987-05-20
JPH041728B2 (en:Method) 1992-01-14

Similar Documents

Publication Publication Date Title
CA1300503C (en) Immunological adjuvant
US4803070A (en) Immunological emulsion adjuvants for polysaccharide vaccines
US9579379B1 (en) Saponin adjuvant compositions and methods relating thereto
AU695802B2 (en) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US5376369A (en) Vaccine adjuvant
JPH09506887A (ja) ワクチン
CA2330610A1 (en) Adjuvant composition and methods for its use
CA2177667C (en) Mammalian vaccine compositions comprising squalene or squalane, lecithin and a polyoxyethylene sorbitan ester as an adjuvant
AU626271B2 (en) Vaccine adjuvant
JPH08505866A (ja) 組換えサブユニット生ワクチン組成物及びその製造方法
KR19980025002A (ko) 개량된 불활성 백신
US6528058B1 (en) Saponin adjuvant composition
Harrison et al. Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants
Johansson et al. Identification of adjuvants that enhance the therapeutic antibody response to host IgE
US20060073171A1 (en) Vaccine composition against malaria
US6689370B1 (en) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
CN1226173A (zh) 脱乙酰壳多糖引起的免疫强化
Stewart-Tull Symposium on immunological adjuvants
JP2000504350A (ja) キトサン誘導性免疫強化
CN1153064A (zh) 病毒疫苗佐剂

Legal Events

Date Code Title Description
MKEX Expiry